Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)

Infection

Volumn 42, Issue 5, 2014, Pages 811-815

  Bruno, R ^a   Carosi, G ^b   Coppola, N ^c   Gaeta, G B ^c   Puoti, M ^d   Santantonio, T ^e   Taliani, G ^f   Armignacco, O ^g   Sagnelli, E ^c   Andreoni, M ^h   Angarano, G ⁱ   Di Perri, G ^j   D'Offizi G ^k   Galli, M ^l   Rizzardini, G ^m  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

^h TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Acute hepatitis; HBV

Indexed keywords

ANTIVIRUS AGENT;

ACUTE DISEASE; HEPATITIS B; HUMAN; ITALY; LIVER TRANSPLANTATION; PRACTICE GUIDELINE; VIROLOGY;

ACUTE DISEASE; ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; ITALY; LIVER TRANSPLANTATION;

EID: 84929517025     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0642-0     Document Type: Review

References (21)

1. Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:96–101.
2. Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;56:775–83.
3. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canby A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256–63.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.
5. Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 2014;59(1):89–97. doi:10.1002/hep.26635.
6. Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol. 2003;69:313–23.
7. Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol. 2013;58:212–6.
8. Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322–8.
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.
10. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012;32:544–53.
11. Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol. 2002;67:454–7.
12. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improve the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.
13. Galli M, Crocchiolo P, Negri C, et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res. 1985;11:665–9.
14. Galský J, Bansky G, Holubová T, Kõnig J. Effect of ursodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol 1999;28:249–53.
15. Fabris P, Tositti G, Mazzella G, Zanetti AR, Nicolin R, Pellizzer G, Benedetti P, de Lalla F. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther. 1999;13:1187–93.
16. Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus activity of N-acetyl-l-cysteine (NAC): new aspects of a well-established drug. Antivir Res. 1996;32:43–53.
17. Gunduz H, Karabay O, Tamer A, et al. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9:2698–700.
18. Evans TW. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16:6–11.
19. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10(4):R108.
20. Schmidt LE, Wang LP, Hansen BA, et al. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl. 2003;9:290–7.
21. Saliba F, Camus C, Durand F, et al. Randomized controlled multicentre trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology 2008;48:LB1.